Mount Sinai study finds SARS-CoV-2 induces robust antibody responses stable for at least 3 months

Research Alert

Research from the Mount Sinai Health System, just posted to pre-print server MedRxiv (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1), shows that the vast majority (more than 90%) of infected individuals with mild-to-moderate COVID 19 experience robust IgG antibody responses against the viral spike protein. The researchers also show that antibody titers (levels) are stable for at least a period of 3 months, and that anti-spike binding titers significantly correlate with neutralization of the SARS-CoV-2 virus. The findings are based on a dataset of 19,860 individuals screened at Mount Sinai Health System in NYC. Understanding the response in mild COVID 19 cases is of high importance since mild and asymptomatic cases constitute the majority of infections. Uncovering the robustness of antibody response, including its longevity and its functionality (neutralizing effects), will be critical to informing serosurveys and determining levels and duration of antibody titers that may be protective from reinfection.
**of note, these observations are in contrast to a recent report that found waning antibody levels 8 weeks post-infection as compared to acute responses**

 

Some top line points from the paper include:

-- Antibodies to SARS-CoV-2 can target many of its encoded proteins. So far, two structural proteins have been utilized as target antigens for serological assays (antibody tests) and characterizing the immune response to the virus. One of them is the abundant nucleoprotein (NP), which is found inside the virus or inside infected cells. The other is the spike protein. The spike contains the receptor binding protein (RBD), which the virus uses to dock to its cellular receptor angiotensin converting enzyme 2 (ACE2), in addition to possessing the machinery that allows fusion of viral and cellular membranes. A number of antibody-based tests targeting NP have been developed and are being used for serological studies. However, due to the biological function of NP and the fact that it's shielded from antibodies by viral or cellular membranes, it's unlikely that NP antibodies can directly neutralize the virus. It's known from other coronoviruses as well as for SARS-CoV-2 that the spike is the main, and potentially the only target for neutralizing antibodies

-- The assay used in this study - an enzyme-linked immunosorbent assay (ELISA) that was initially developed in early 2020, has been extensively used in research and was established in Mount Sinai's CLIA laboratory where it received New York State DOH and FDA emergency use authorization - is based on the spike protein. The Mount Sinai ELISA antibody test has sensitivity of 92.5% and specificity of 100%. 

-- In March 2020, Mount Sinai began to screen individuals for antibodies to recruit volunteers as donors for convalescent plasma therapy. By July 2020, Mount Sinai has screened more than 51,000 individuals using the Mount Sinai ELISA test, with 19,763 of them being positive (defined as detectible antibodies to the spike protein at a titer of 1:80 or higher)

-- The CLIA ELISA set up results in a discrete titer at a dilution of either 1:80, 1:160, 1:320, 1:960 or at/above 1:2880.  The titer of 80-160 is low, 320 is moderate and 960 and above is high. For plasma therapy, titers of 320 or higher were deemed as eligible as per FDA protocol. Of the 19,763 positive samples, more than 92% have moderate to high titers of anti-spike antibodies. (see Figure 1 of the study)

-- To determine if antibodies induced against the spike protein exert neutralizing activity, the team performed a well-established, quantitative microneutralization assay based on authentic SARS-CoV-2 with 120 samples of known ELISA titers ranging from 'negative' to 2880. They found that appx. 50% of sera in the 80-160 range had neutralizing activity, 90% in the 320 range had neutralization activity and all sera in the 960-2880 range had neutralizing activity. 

-- To assess longevity of the antibody response to the spike, the team recalled 121 plasma donors at a variety of titer levels for repeat antibody testing about 3 months post-symptom onset. In the higher titer range they observed a slight drop in titer between the two time points and simultaneously saw an increase in individuals who initially had titers between 80 - 320. The research team plans to follow this cohort over longer intervals of time. 

-- For many different viral infections, correlated of protection have been established. These correlates are usually based on a specific level of antibody acquired through vaccination or natural infection that significantly reduces the risk of (re)infection. These titers have facilitated vaccine development significantly. The Mount Sinai data reveals antibody binding titers to the spike protein correlate significantly with neutralization with SARS-CoV-2 and the vast majority of individuals with antibody titers of 320 or higher show neutralizing activity in their serum. It will be important to work towards identifying a correlate of protection for SARS CoV 2.  

-- While this cannot provide conclusive evidence that these antibody responses protect from re-infection, researchers believe it's very likely they will decrease the odds ratio of getting re-infected and may attenuate disease in the case of breakthrough infection. 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 2781
Released: 4-Aug-2020 11:55 AM EDT
ACTG Announces Launch of Novel Clinical Trial Testing Multiple Therapeutics to Treat COVID-19
University of California, Los Angeles (UCLA), Health Sciences

The AIDS Clinical Trials Group (ACTG) has initiated the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial.

Newswise:Video Embedded covid-19-study-confirms-low-transmission-in-educational-settings2
VIDEO
Released: 4-Aug-2020 11:20 AM EDT
COVID-19 study confirms low transmission in educational settings
University of Sydney

The rate of COVID-19 transmission in New South Wales (NSW) educational settings was extremely limited during the first wave of COVID-19, research findings published today in The Lancet Journal of Child and Adolescent Health have shown.

Newswise: Droplet Spread from Humans Doesn’t Always Follow Airflow
31-Jul-2020 3:15 PM EDT
Droplet Spread from Humans Doesn’t Always Follow Airflow
American Institute of Physics (AIP)

If aerosol transmission of COVID-19 is confirmed to be significant, as suspected, we will need to reconsider guidelines on social distancing, ventilation systems and shared spaces. Researchers in the U.K. believe a better understanding of different droplet behaviors and their different dispersion mechanisms is also needed. In Physics of Fluids, the group presents a model that demarcates differently sized droplets. This has implications for understanding the spread of airborne diseases, because the dispersion tests revealed the absence of intermediate-sized droplets.

Released: 4-Aug-2020 10:30 AM EDT
COVID-19 study confirms low transmission in educational settings
University of Sydney

The rate of COVID-19 transmission in New South Wales (NSW) educational settings was extremely limited during the first wave of COVID-19, research findings published today in The Lancet Journal of Child and Adolescent Health have shown.

Newswise: Researchers develop new mouse model for SARS-CoV-2
Released: 4-Aug-2020 10:00 AM EDT
Researchers develop new mouse model for SARS-CoV-2
The Rockefeller University Press

Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus. The study, published today in the Journal of Experimental Medicine (JEM), also suggests that, rather than protecting the lungs, key antiviral signaling proteins may actually cause much of the tissue damage associated with COVID-19.

Newswise: Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
Released: 4-Aug-2020 10:00 AM EDT
Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
La Jolla Institute for Immunology

A new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19.

Newswise:Video Embedded protocol-needed-to-monitor-covid-19-disease-course
VIDEO
Released: 3-Aug-2020 9:05 PM EDT
Protocol needed to monitor COVID-19 disease course
University of Washington School of Medicine and UW Medicine

Patients with underlying conditions such as asthma or other lung problems should be checked on regularly by pulmonologists or primary-care doctors for at least six months. Some will need to be monitored for one to three years, according to a new opinion piece posted online today in The Lancet-Respiratory Medicine.

Newswise: UM Cardiology Researchers Studying How COVID-19 Affects the Heart
Released: 3-Aug-2020 3:10 PM EDT
UM Cardiology Researchers Studying How COVID-19 Affects the Heart
University of Miami Health System, Miller School of Medicine

COVID-19 is shown to impact the heart and, in some cases, have long-lasting cardiac effects. To discover the extent to which COVID-19 affects the heart, cardiologists and researchers with the University of Miami Miller School of Medicine have begun multiple studies.

Newswise: Tackling the Bioethics Challenges Raised by COVID-19
Released: 3-Aug-2020 3:05 PM EDT
Tackling the Bioethics Challenges Raised by COVID-19
University of Pennsylvania School of Nursing

The diverse situations experienced by health-care workers during the COVID-19 pandemic often present serious ethical challenges. From the allocation of resources and triage protocols to health-care worker and patient rights and the management of clinical trials, new ethical questions have come to the forefront of today’s global public health emergency.


Showing results

110 of 2781

close
1.0137